Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 11/20 | 0.55 |
| ▸ | NPY1R | P25929 | 6/20 | 0.55 |
| ▸ | NPY2R | P49146 | 4/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 3/20 | 0.46 |
| ▸ | FNTB | P49356 | 3/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30903447 | 0.98 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RNAALAD2 | |
| SCHEMBL30770172 | 0.96 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RNAALAD2 | |
| SCHEMBL30866936 | 0.96 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RNAALAD2 | |
| SCHEMBL31410842 | 0.94 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RNAALAD2 | |
| SCHEMBL4048021 | 0.94 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RGNPAT | |
| SCHEMBL29577090 | 0.94 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RGNPAT | |
| SCHEMBL31184527 | 0.94 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RGNPAT | |
| SCHEMBL4048028 | 0.94 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5RGNPAT | |
| SCHEMBL31356561 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RFOLH1 | |
| SCHEMBL31190179 | 0.93 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RNAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | Edinburgh Molecular Imaging Limited (GB) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273830-A1 | COMPOUNDS AND METHODS OF USE | VIP, QPCT, CALCRL | NPY4R 888/4885NPY1R 590/4885NPY2R 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.